MétaCan
Menu
← Back to cohort
Record W4416877415 · doi:10.1681/asn.2025pdej0qvx

Protection Against Incidences of Serious Cardiovascular Events Study with Daily Fish Oil Supplementation in Patients on Dialysis (PISCES)

2025· article· en· W4416877415 on OpenAlexaffabout
Charmaine E. Lok, Brenda R. Hemmelgarn, Louise Moist, Kevan R. Polkinghorne, George Tomlinson, Paul Tam, Marcello Tonelli

Bibliographic record

VenueJournal of the American Society of Nephrology · 2025
Typearticle
Languageen
FieldNursing
TopicFatty Acid Research and Health
Canadian institutionsUniversity of CalgaryThe Scarborough HospitalWestern UniversityUniversity of AlbertaUniversity of TorontoUniversity Health Network
Fundersnot available
KeywordsFish oilDialysisHemodialysisKidney diseaseIncidence (geometry)

Abstract

fetched live from OpenAlex

Background: Cardiovascular (CV) events occur frequently and is the leading cause of mortality in patients receiving maintenance hemodialysis (HD), yet effective preventive therapies remain limited. Omega-3 polyunsaturated fatty acids (n-3 PUFA)- eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have shown potential CV benefits in the general population, although their efficacy in the HD population is uncertain. Methods: PISCES was a multicenter double-blind placebo-controlled RCT evaluating the effect of daily oral supplementation with 4 g of n-3 PUFA (1.6 g EPA, 0.8 g DHA) vs placebo in 1228 adults on maintenance HD (26 sites) x 3.5 years. The primary endpoint was the rate of all serious CV events (CV death, non-fatal myocardial infarction, stroke, peripheral vascular disease requiring amputation). Secondary outcomes included the primary outcome plus all-cause mortality and individual components of the primary outcome. Results: The rate of the primary outcome was significantly lower in the n-3 PUFA group (0.31/1000 days) compared to placebo (0.61/1000 days) (Fig 1); HR 0.57 (95% CI: 0.47-0.70), p<0.0001 (Fig 2). The rate of the secondary outcome of CV events and all-cause mortality was significantly reduced (HR 0.77; 95% CI:0.65–0.90; p<0.0001). Benefits were consistent among those with (HR 0.50; 95% CI: 0.37-0.67] and without (HR 0.55; 95% CI: 0.40-0.76; p < 0.000) prior CV events. Each component of the primary outcome occured less frequently in n-3 PUFA group (Fig 2). There were no safety signals. Conclusion: The rate of serious CV events was significantly lower in patients on maintenance HD who received daily n-3 PUFA compared with placebo. Funding: Other NIH Support - Heart and Stroke Foundation of Canada (G-15- 0009388), Lawson Health Research Institute, Peter Munk Cardiac Care Innovation Fund (CMT-1516-237), Kidney CARE Network International, National Health and Medical Research Council (APP1123392) (NHMRC, Australia). Personnel award (Dr. Charmaine Lok) - Heart and Stroke Foundation (#7511-A), Ontario Provincial Office. Private donation - Mr. Alexander Epstein., Commercial Support - In Kind contribution from DSM (previously Ocean Nutrition Canada), Private Foundation Support, Government Support - Non-U.S.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.004
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0030.003
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.014
GPT teacher head0.295
Teacher spread0.281 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueJournal of the American Society of Nephrology→Same topicFatty Acid Research and Health→French-language works237,207→